Potential approaches to prevent uncommon hemolytic side effects of AB0 antibodies in plasma derivatives

Biologicals

Volumn 33, Issue 1, 2005, Pages 41-48

  Buchta, Christoph ^a   MacHer, Maria ^a   Höcker, Paul ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD GROUP A ANTIBODY; BLOOD GROUP ANTIBODY; BLOOD GROUP B ANTIBODY; BLOOD GROUP D ANTIBODY; DESMOPRESSIN; ERYTHROCYTE ANTIBODY; IMMUNOGLOBULIN; PLASMA SUBSTITUTE; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTICLE; BLOOD DONOR; BLOOD GROUP AB; BLOOD GROUP ABO SYSTEM; BLOOD TRANSFUSION REACTION; DRUG MEGADOSE; DRUG POTENCY; EUROPEAN UNION; HEALTH CARE COST; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; JAPAN; LEGAL ASPECT; MEDICATION ERROR; PRIORITY JOURNAL; SIDE EFFECT; THROMBOEMBOLISM; UNITED STATES;

EID: 13844272632     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biologicals.2004.10.004     Document Type: Article

References (69)

1. P.D. Issitt, and D.J. Anstee Applied blood group serology 4th ed. 1998 Montgomery Scientific Publications
2. J. Rushin, D.H. Rumsey, C.A. Ewing, and S.G. Sandler Detection of multiple passively acquired alloantibodies following infusions of IV Rh immune globulin Transfusion 40 2000 551 554
3. M.A. Denborough, J.H. Downing, and A.G. Doig Serum blood group substances and AB0 hemolytic disease Br J Haematol 16 1969 103 109
4. A.M. Holburn, and C.A. Masters The radioimmunoassay of serum and salivary blood group A and Lea glycoproteins Br J Haematol 28 1974 157 167
5. P.L. Mollison, C.P. Engelfriet, and M. Contreras Blood transfusion in clinical medicine 9th ed. 1987 Blackwell Scientific Publications
6. M.J. Inwood, and B. Zuliani Anti-A hemolytic transfusion with packed 0 cells Ann Intern Med 89 1978 515 516
7. J.K. Smith, P.J. Bowell, E. Bidwell, and H.H. Gunson Anti-A haemagglutinins in factor VIII concentrates J Clin Pathol 33 10 1980 954 957
8. R.A. Seeler, M. Telischi, P.L. Langehennig, and J.B. Ashenhurst Comparison of anti-A and anti-B titers in factor VIII and IX concentrates J Pediatr 89 1 1976 87 89
9. L.A. Rosati, B. Barnes, H.A. Obermann, and J.A. Penner Hemolytic anemia due to anti-A in concentrated antihemophilic factor preparations Transfusion 10 1970 139 141
10. G.P. Tamagnini, K.M. Dormandy, D. Ellis, and W. Maycock Factor VIII concentrate in hemophilia Lancet 2 1975 188 [letter]
11. V. Hach-Wunderle, D. Teixidor, P. Zumpe, P. Kuhnl, and I. Scharrer Anti-A in factor VIII concentrate: a cause of severe hemolysis in a patient with acquired factor VIII:C antibodies Infusionstherapie 16 1989 100 101
12. R.A. Seeler Hemolysis due to anti-A and anti-B in factor VIII preparations Arch Intern Med 130 1 1972 101 103
13. N.S. Soni, A.R. Patel, R.M. Vohra, and P.C. Shah Hemophiliac with hemolytic anemia resulting from factor VIII concentrate Acta Haematol 58 5 1977 294 297
14. E.P. Orringer, M.J. Koury, P.M. Blatt, and H.R. Roberts Hemolysis caused by factor VIII concentrates Arch Intern Med 136 9 1976 1018 1020
15. G. Shulman, J.O. Ballard, and M.E. Eyster Changes in plasma haptoglobin and alpha-2-macroglobulin in hemophiliacs receiving factor replacement therapy Am J Hematol 18 3 1985 223 233
16. N. Egberg, and M. Blomback High frequency of low plasma haptoglobin values found in hemophilia A patients on prophylactic treatment with factor VIII concentrates - a sign of hemolysis? Thromb Haemost 46 2 1981 554 557
17. M.V. Ragni, J.A. Spero, P. Larson, G. Ramsey, and J.H. Lewis Immune hemolysis by isohemagglutinins in factor IX concentrates Transfusion 27 1987 292 293
18. V.M. Robertson, L.G. Dickson, E.H. Romond, and R.C. Ash Positive antiglobulin tests due to intravenous immunoglobulin in patients who received bone marrow transplant Transfusion 27 1987 28 31
19. H.A. Obermann, and M.L. Beck Red blood cell sensitization due to unexpected Rh antibodies in immune serum globulin Transfusion 11 1971 382 384
20. P. Niosi, J. Lundberg, J. McCullough, B.H. Park, and D.W. Biggar Blood group antibodies in human immune serum globulin N Engl J Med 285 1971 1435 1436
21. G.E. Lang, and B. Veldhuis Immune serum globulin: a cause for anti-Rh0(D) passive sensitization Am J Clin Pathol 60 1973 205 207
22. J.M. Gordon, P. Cohen, and J.S. Finlayson Levels of anti-A and anti-B in commercial immune globulins Transfusion 20 1980 90 92
23. A.G. Brox, D. Cournoyer, M. Sternbach, and G. Spurrl Hemolytic anemia following intravenous gamma globulin administration Am J Med 82 1987 633 635
24. A.G. Brox, D. Cournoyer, M. Sternbach, and G. Spurll Hemolytic anemia following intravenous gamma globulin administration Am J Med 93 1992 114 115
25. A. Salama, C. Mueller-Eckhardt, and V. Kieffel Effect of intravenous immunoglobulin in immune thrombocytopenia Lancet ii 1983 193 195
26. E.A. Copelan, P.L. Strohm, M.S. Kennedy, and P.J. Tutschka Hemolysis following intravenous immune globulin therapy Transfusion 26 1996 410 412
27. J.R. Wilson, N. Bhoopalam, and M. Fisher Hemolytic anemia associated with intravenous immunoglobulin Muscle Nerve 20 9 1997 1142 1145
28. E. Strobel, J. Wullenweber, and J. Peters Demonstration of isoagglutinins in intravenously applicable immunoglobulin preparations Beitr Infusionsther Transfusionsmed 32 1994 200 202
29. H.C. Kim, C.L. Park, J.H. Cowan III, F.D. Fattori, and C.S. August Massive intravascular hemolysis associated with intravenous immunoglobulin in bone marrow transplant recipients Am J Pediatr Hematol Oncol 10 1988 69 74
30. M. Nakagawa, N. Watanabe, M. Okuno, M. Kondo, H. Okagawa, and T. Taga Severe hemolytic anemia following high-dose intravenous immunoglobulin administration in a patient with Kawasaki disease Am J Hematol 63 3 2000 160 161
31. M. Stangel, H.P. Hartung, P. Marx, and R. Gold Side effects of high-dose intravenous immunoglobulins Clin Neuropharmacol 20 5 1997 385 393
32. Y. Sherer, Y. Levy, P. Langevitz, L. Rauova, F. Fabrizzi, and Y. Schoenfeld Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases Pharmacology 62 3 2001 133 137
33. S.A. Misbah, and H.M. Chapel Adverse effects of intravenous immunoglobulin Drug Saf 9 4 1993 254 262
34. R.H. Buckley, and R.I. Schiff The use of intravenous immune globulin in immunodeficiency diseases N Engl J Med 325 1991 110 117
35. C. Duhem, M.A. Dicato, and F. Ries Side effects of intravenous immune globulins Clin Exp Immunol 97 suppl 1 1994 79 83
36. S. Nakamura, T. Yoshida, S. Ohtake, and T. Matsuda Hemolysis due to high-dose intravenous gammaglobulin treatment for patients with idiopathic thrombocytopenic purpura Acta Haematol 76 1986 115 118
37. J. Yasuda, H. Saito, J. Ozaki, and S. Asakawa AB0 blood group activities in human albumin preparations Jpn J Med Sci Biol 34 5 1981 271 279
38. J.L. Tullis Albumin. 1. Background and use JAMA 237 1977 355 360
39. L.A. Garcia, and G.A. Ordonez The use of pluronic polyols in the precipitation of plasma proteins and its application in the preparation of plasma derivatives Transfusion 16 1 1976 32 41
40. European Directorate for the Quality of Medicines. European Pharmacopoeia, 4th ed., 2002, Method 2.6.20.
41. European Directorate for the Quality of Medicines. European Pharmacopoeia, 2nd ed., 1986, Method VIII.12.
42. USP XXI, General information, (1041) Biologics, 1985 p. 1285.
43. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm
44. Association of Biologicals Manufacturers of Japan: Minimum Requirements for Biological Products; Ministry of Health and Welfare, Association of Biologicals Manufacturers of Japan, Tokyo; 1993.
45. A.E. Preston, and A. Barr The plasma concentration of Factor VIII in the normal population. II. The effects of age, sex and blood group Br J Haematol 10 1964 238
46. G. Garratty Do blood groups have a biological role? G. Garratty Immunobiology of Transfusion Medicine 1994 Marcel Dekker New York 201
47. I.M. Nilsson, H. Walter, M. Mikaelsson, and H. Vilhardt Factor VIII concentrate prepared from DDAVP stimulated blood donor plasma Scand J Haematol 22 1979 42 46
48. P.M. Mannucci Desmopressin (DDAVP) for treatment of disorders of hemostasis Prog Hemostas Thromb 8 1986 19 45
49. M. Mikaelsson, I.M. Nilsson, H. Vilhardt, and B. Wiechel Factor VIII concentrate prepared from blood doors stimulated with intranasal DDAVP Transfusion 22 1982 229 233
50. M.J. Randels, R.G. Strauss, D. Cordle, T.A. Koerner, and A.S. Floss Donor reactions during DDAVP-stimulated plasmapheresis J Clin Apheresis 7 2 1992 78 80
51. A.L. Dunn, M.J. Powers, M.J. Ribeiro, F.R. Rickles, and T.C. Abshire Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients Haemophilia 6 2000 11 14
52. F.J. Grundbacher Genetics of anti-A and anti-B levels Transfusion 16 1976 48 55
53. F.J. Grundbacher Quantity of haemolytic anti-A and anti-B in individuals of a human population: correlations with isoagglutinins and effects of the individual's age and sex Z Immunitatsforsch Allerg Klin Immunol 134 4 1967 Dec 317 349
54. L. Daufi, and P. Rondell Universality of anti-A and anti-B human isolysins Vox Sang 21 1971 81 85
55. W.K. Roth, M. Weber, and W. Seifried Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus and HIV-1 in a blood bank setting Lancet 353 1999 359 363
56. W.K. Roth, and E. Seifried Reducing the residual risk of transfusion-transmitted viruses: mini-pool or single-donation NAT? Transfusion 41 6 2001 June 845 847
57. Dr. Rudolf Worofka, Baxter BioScience, Vienna, Austria, Personal communication January 16th, 2003.
58. T.M.S. Chang Blood compatible coating of synthetic immunoadsorbents Trans Am Soc Artif Intern Organs 26 1980 546 549
59. W.I. Bensinger, C.D. Buckner, and R.A. Clift Whole blood immunoadsorption of anti-A or anti-B antibodies Vox Sang 48 6 1985 357 361
60. W.I. Bensinger, D.A. Baker, C.D. Buckner, R.A. Clift, and E.D. Thomas Immunoadsorption for removal of A and B blood group substances N Engl J Med 304 1981 160 162
61. W.I. Bensinger, D.A. Baker, C.D. Buckner, R.A. Clift, and E.D. Thomas In vitro and in vivo removal of anti-A erythrocyte antibody by adsorption to a synthetic immunoadsorbent Transfusion 21 1981 335 342
62. M.A. Mazid, and M. Kaplan An improved affinity support and immunoadsorbent with a synthetic blood group oligosaccharide and a polymer coating for hemoperfusion J Appl Biomater 3 1 1992 9 15
63. L. Blomberg, T. Bratt, M.A. Chester, and B. Hansson Improved removal of anti-A and anti-B antibodies from plasma using blood-group-active haptens Vox Sang 65 1993 126 135
64. M.S. Hout, K.E. LeJeune, T.M. Schaack, T.K. Bristow, and W.J. Federspiel Specific removal of anti-A and anti-B antibodies by using modified dialysis filters ASAIO J 46 6 2000 702 706
65. J.V. Linden, K. Wagner, A.E. Voytovich, and J. Sheehan Transfusion errors in New York State: an analysis of 10 year's experience Transfusion 40 2000 1207 1213
66. P.L. Baele, M. De Bruyere, V. Deneys, E. Dupont, J. Flament, and M. Lambermont Bedside transfusion errors. A prospective study by the Belgium SAnGUIS Group Vox Sang 66 1994 117 121
67. J. Ibojie, and S.J. Urbaniak Comparing near misses with actual mistransfusion events: a more accurate reflection of transfusion errors Br J Haematol 108 2000 458 460
68. G. Caspari, U. Alpen, and A. Greinacher The risk of transfusion to the wrong patient in Germany Transfusion 42 2002 1238 1239 [letter]
69. M.J. Thomas, S.A. Misbah, H.M. Chapel, M. Jones, G. Elrington, and J. Newsom-Davis Hemolysis after high-dose intravenous Ig Blood 82 1993 3789 [letter]